

 ISSN (O): 2320-5407 ISSN (P): 3107-4928	Journal Homepage: www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR) Article DOI:10.21474/IJAR01/23847 DOI URL: http://dx.doi.org/10.21474/IJAR01/23847	
--	--	---

REVIEW ARTICLE

TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES

N.Vijaya Lakshmi Reddy, M. Sarika, V.Deepika, M. Hima Bindu and Syed Ahad Hussain

1. Department of Pharmacy, Prathap Narendar Reddy College of Pharmacy, Vaageswari College of Pharmacy.

Manuscript Info

Manuscript History

Received: 12 May 2026

Final Accepted: 14 June 2026

Published: July 2026

Keywords: -

PROTAC; targeted protein degradation;
ubiquitin-proteasome system; cancer
therapy; molecular glues; drug
discovery; vepdegestrant; ARV-110

Abstract

Targeted protein degradation (TPD) has emerged as one of the most transformational approaches in current drug development, fundamentally challenging the long-standing assumption that small compounds must only inhibit their protein targets. Among TPD methods, proteolysis-targeting chimeras (PROTACs) have attracted considerable attention from both academic researchers and clinicians, giving a catalytic mechanism that permits the total removal of disease-driving proteins rather than just reducing their activity. This thorough analysis investigates the molecular basis of PROTAC technology, tracking its progression from an elegant intellectual notion to a clinically approved treatment platform. We discuss the molecular machinery of the ubiquitin - proteasome system that PROTACs exploit, analyze the structural design principles underlying effective degrader molecules, and provide a detailed survey of the current clinical landscape, including the landmark progression of vepdegestrant (ARV-471) through Phase III clinical evaluation, culminating in U.S. Food and Drug Administration (FDA) approval on May 1, 2026. The paper critically assesses issues including the "beyond Rule of Five" physicochemical features of PROTACs, oral bioavailability restrictions, resistance mechanisms, and tissue penetration barriers. Furthermore, we evaluate promising next-generation TPD technologies-molecular glues, LYTACs, AUTACs, and antibody-based degraders-that promise to broaden the therapeutic reach beyond the proteasome. By combining molecular insights with clinical data, this review presents a path for the continuing evolution of protein degradation techniques in cancer and beyond.

"© 2026 by the Author(s). Published by IJAR under CC BY 4.0. Unrestricted use allowed with credit to the author."

Introduction:-

For several decades, drug discovery has largely relied on the development of small-molecule inhibitors that suppress the activity of disease-associated proteins through occupancy-driven pharmacology. Although this strategy has produced numerous successful therapeutics, a substantial proportion of the human proteome remains inaccessible because many disease-associated proteins lack suitable ligand-binding pockets or possess predominantly scaffolding

Corresponding Author:- Syed Ahad Hussain

Address:-Department of Pharmacy, Vaageswari College of Pharmacy.

or regulatory functions rather than enzymatic activity. Consequently, these proteins have traditionally been regarded as "undruggable" targets.

Targeted protein degradation (TPD) has emerged as an innovative therapeutic paradigm that overcomes many of these limitations by exploiting the cell's endogenous protein quality-control machinery to selectively eliminate pathogenic proteins. Among the various TPD technologies, proteolysis-targeting chimeras (PROTACs) have attracted considerable attention because they function through an event-driven mechanism that induces ubiquitination and subsequent proteasomal degradation of target proteins rather than simply inhibiting their activity. This catalytic mode of action enables sustained pharmacological effects, sub-stoichiometric activity, and the potential to overcome several mechanisms of acquired drug resistance.

The preceding two decades have seen the translation of this notion from intellectual curiosity to therapeutic reality. The first PROTAC entered human clinical trials in 2019, and over the following years several degraders advanced through clinical development. A landmark milestone was achieved on May 1, 2026, when the U.S. Food and Drug Administration (FDA) approved vepdegestrant (ARV-471), developed by Arvinas and Pfizer and marketed as VEPPANU, for the treatment of adults with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. This approval marked the first FDA-approved PROTAC therapy and represented a major milestone in the clinical translation of targeted protein degradation. This remarkable progress emphasizes the therapeutic promise of controlled protein breakdown and has sparked an explosion of research effort across academia and business. This review presents a detailed evaluation of PROTAC technology in cancer treatment, combining mechanistic discoveries with clinical advancements and addressing the hurdles that must be solved to reach the full promise of this paradigm-shifting strategy.

The Ubiquitin-Proteasome System: Cellular Machinery for Protein Quality Control:- Physiological Role of the UPS:-

To appreciate the mechanistic basis of PROTAC technology, one must first grasp the ubiquitin-proteasome system (UPS)-the cell's fundamental mechanism for controlled protein breakdown. The UPS maintains cellular homeostasis by removing misfolded, damaged, or unneeded proteins, consequently regulating important physiological activities like cell cycle progression, signal transmission, transcriptional control, and stress responses.

The UPS acts using a complex three-step enzymatic cascade:-

Ubiquitin Activation (E1): The process commences with ubiquitin-activating enzymes (E1s) that activate ubiquitin in an ATP-dependent reaction, generating a thioester link between ubiquitin's C-terminus and the E1 active site cysteine. In humans, two E1 enzymes-UBA1 and UBA6-serve as the entry sites for all ubiquitin conjugation. **Ubiquitin Conjugation (E2):** Activated ubiquitin is transported to ubiquitin-conjugating enzymes (E2s), of which about 40 occur in the human genome. These E2s determine the topology of the ubiquitin chains that will be assembled. **Ubiquitin Ligation (E3):** Finally, ubiquitin ligases (E3s)-numbering over 600 in humans-confer substrate specificity by identifying degradation signals (degrons) on target proteins and facilitating ubiquitin transfer from the E2 to substrate lysine residues. The ensuing polyubiquitin chains, especially those connected by lysine-48 (K48) of ubiquitin, serve as recognition signals for the 26S proteasome-a large ~2.5 MDa proteolytic complex that unfolds and destroys ubiquitinated substrates into tiny peptides.

Ligases: The Specificity Determinants:-

The enormous variety of E3 ligases provides the molecular foundation for selective protein breakdown.

These enzymes come into three primary families:-

Really Interesting New Gene (RING) finger ligases: The biggest family, containing the cullin-RING ligases (CRLs). CRLs form the biggest class of E3s, with eight cullin scaffolds (CUL1, 2, 3, 4A, 4B, 5, 7, and 9) building multi-subunit complexes. The substrate receptor subunit determines target specificity. Notable examples are SCF^β-TRCP, VHL-BC-CUL2, and the CRL4^{CRBN} complex.

Homologous to E6-AP C-Terminus (HECT) domain ligases: These ~28 enzymes, including E6AP and NEDD4 family members, create thioester intermediates with ubiquitin before transfer to substrates.

RING-between-RING (RBR) ligases: These enzymes, including Parkin, incorporate elements of both RING and HECT processes.

For PROTAC development, the most commonly exploited E3 ligases are CRBN (cereblon), VHL (von Hippel-Lindau), cIAP (cellular inhibitor of apoptosis proteins), and MDM2 (mouse double minute 2 homolog), each offering distinct tissue expression patterns, substrate preferences, and chemical tractability.

Mechanisms of PROTAC-Mediated Protein Degradation:-

The mechanism of PROTAC-induced protein degradation represents a fundamental departure from traditional pharmacology, operating through an elegant catalytic cycle that harnesses the cell's endogenous protein quality control machinery. Understanding this mechanism at molecular detail is essential for rational degrader design, troubleshooting failed compounds, and predicting clinical behavior. This section provides a comprehensive examination of the mechanistic steps, catalytic pharmacology, and concentration-dependent phenomena that define PROTAC activity.

The Ternary Complex: Induced Proximity as the Central Mechanism:-

PROTACs work as molecular matchmakers, producing artificial protein-protein interactions that would not exist under normal settings. These heterobifunctional compounds consist of three structural elements: a ligand binding the protein of interest (POI), a ligand engaging an E3 ubiquitin ligase, and a linker joining these two warheads. The process progresses via numerous coordinated stages that translate individual binding events into productive protein breakdown.

Step 1: Binary Complex Formation and Encounter Dynamics:-

The degradation cascade commences when the PROTAC contacts either the POI or the E3 ligase, generating a binary complex. This first binding event follows normal mass action kinetics, with the concentration of binary complex defined by the binding affinity (K_d) of the respective warhead and the local concentration of binding partners. Critically, the binding affinity of each warhead must be adequate to promote initial recruitment at cellular concentrations, while high affinity alone does not ensure successful destruction. The encounter between PROTAC and its initial binding partner happens via three-dimensional diffusion in the cellular milieu, with rates affected by molecular crowding, viscosity, and subcellular compartmentalization. Recent single-molecule investigations have indicated that binary complex formation is typically diffusion-limited, with association rates (k_{on}) reaching the theoretical maximum for protein-small molecule interactions ($\sim 10^8$ - 10^9 M⁻¹s⁻¹). The dissociation rate (k_{off}) then affects complex longevity, with longer residence durations increasing the possibility of productive ternary complex formation.

Step 2: Ternary Complex Assembly and Induced Proximity:-

The binary PROTAC-ligase or PROTAC-POI complex contacts its complementary binding partner, creating the critical ternary complex (E3-PROTAC-POI). This increased closeness puts the target protein into the catalytic vicinity of the E2-E3 ubiquitination machinery, marking the key mechanistic novelty of PROTAC technology.

The development of the ternary complex is guided by the rules of induced protein-protein interactions:

Cooperativity: The binding of PROTAC to one protein may promote (positive cooperativity) or diminish (negative cooperativity) binding to the second protein. Positive cooperativity, indicated by cooperative binding constants (α) larger than 1, stabilizes the ternary complex beyond what would be anticipated from separate binding processes. Structural investigations have demonstrated that good protein-protein interactions between the POI and E3 ligase-mediated by comparable surface charges, hydrogen bonds, and hydrophobic patches-can contribute considerably to ternary complex stability.

Conformational Selection: The ternary complex reflects a particular conformational state picked from an array of potential arrangements. The linker must adopt a shape that places the E3 ligase within ubiquitination range of surface lysines on the POI, often needing the E2 active site to be within 20-50 Å of acceptor lysines.

Kinetics of Assembly: The pace of ternary complex formation relies on the concentrations of all components, the association rate constants, and the stability of intermediate binary complexes. Mathematical models considering PROTACs as enzyme-substrate systems have indicated that ternary complex formation frequently follows pre-equilibrium kinetics, where binary complexes quickly equilibrate before slowly transitioning to the productive ternary state.

Step 3: Polyubiquitination and Chain Topology:-

After the ternary complex forms, the transfer of many ubiquitin molecules is catalyzed by the E3 ligase, which is now located next to the POI. Several biological processes are involved in this process:

E2 loading: To create the catalytically capable E2-E3-substrate assembly, the E3 ligase enlists an E2 ubiquitin-conjugating enzyme that is charged with ubiquitin.

Ubiquitin Transfer: The C-terminus of ubiquitin and the ϵ -amino group of a lysine residue on the POI create an isopeptide bond, which is catalyzed by the E3 ligase. Chain construction is based on this first ubiquitin attachment (monoubiquitination).

Chain Elongation: Additional ubiquitin molecules are bonded to the associated ubiquitin, resulting in polyubiquitin chains. The topology of these chains is crucial for proteasomal recognition.

- K48-linked chains are the classic degradation signal, where each ubiquitin is connected by lysine-48 to the preceding ubiquitin. Chains of four or more K48-linked ubiquitins act as the major signal for proteasomal breakdown.

- K63-linked chains have traditionally been associated with non-proteolytic signaling (DNA repair, endocytosis, NF- κ B activation). However, new data suggests that they may trigger proteasomal breakdown by seeding the development of branching K48/K63 chains.

Branched chains: Mixed or branching ubiquitin chains with K48 and K63 connections have emerged as strong degradation signals. The branching structure may increase binding for proteasomal ubiquitin receptors or inhibit deubiquitinase activity.

- K11-linked chains, especially those formed by the APC/C E3 ligase, also indicate proteasomal breakdown. The combinatorial variety of ubiquitin chain topologies offers a broad signaling repertoire that PROTACs use.

Recent quantitative investigations employing designed ubiquitin chain substrates have demonstrated that K48 chains including three or more ubiquitins cause destruction within minutes, but shorter chains or alternative topologies may provide inadequate signals or result in fast deubiquitination.

Step 4: Proteasomal Recognition and Processing:-

The polyubiquitinated POI is recognized by ubiquitin receptors on the 19S regulatory particle of the 26S proteasome. This large ~2.5 MDa proteolytic machine comprises of a 20S catalytic core particle flanked by 19S regulatory particles.

Recognition: Ubiquitin receptors include Rpn1, Rpn10, and Rpn13 identify and bind polyubiquitin chains, recruiting the substrate to the proteasome. The affinity of this interaction relies on chain length and structure, with longer chains and branching topologies displaying stronger affinity.

Deubiquitination: Before breakdown, ubiquitin chains are eliminated by deubiquitinating enzymes (DUBs) associated with the 19S particle, including Rpn11 and Usp14. This deubiquitination has twin purposes: recycling ubiquitin for future rounds of conjugation and ensuring that only committed substrates access the catalytic core.

Unfolding and Translocation: ATPases in the 19S base (Rpt1-6) employ ATP hydrolysis to unfold the substrate protein and thread it through a small channel into the 20S core. This unfolding process is rate-limiting for many substrates and explains why certain proteins resist breakdown despite ubiquitination.

Proteolysis: Within the 20S core, threonine protease active sites cleave the unfolded polypeptide into tiny peptides (usually 3-25 amino acids), which are released for subsequent processing or presentation on MHC class I molecules.

Step 5: PROTAC Recycling and Catalytic Turnover:-

Following target ubiquitination and liberation from the E3 ligase, the PROTAC is free to bind another POI molecule, allowing sub-stoichiometric, catalytic destruction. This recycling process is what separates PROTACs from stoichiometric inhibitors and underlines their distinct pharmacological characteristics. The catalytic effectiveness of a PROTAC may be evaluated by its turnover number-the number of target molecules destroyed per PROTAC molecule before the PROTAC is metabolized or removed. Experimental observations employing radiolabeled PROTACs have indicated turnover numbers ranging from 2-10 for early compounds to >100 for optimized degraders. This catalytic amplification implies that PROTACs may be efficacious at concentrations much below their target protein levels, a characteristic with major consequences for medication dosage and safety.

Catalytic Pharmacology: Beyond Occupancy-Based Inhibition:-

The catalytic nature of PROTACs distinguishes them fundamentally from traditional inhibitors and establishes a new paradigm for pharmacological action. While inhibitors require sustained target occupancy to maintain pharmacological effect-often necessitating high drug concentrations, continuous administration, and frequent dosing-PROTACs can achieve therapeutic effects at lower concentrations by acting as catalysts for protein destruction.

Event-Driven vs. Occupancy-Driven Pharmacology:-

Traditional small-molecule inhibitors work using an occupancy-driven model: the drug must stay coupled to its target to block activity, and dissociation restores target function. This generates a direct link between drug concentration, target occupancy, and pharmacological impact. The duration of action is governed by pharmacokinetics-how long the medication persists in the body at concentrations adequate for target binding.

PROTACs, in contrast, work in an event-driven model: each contact between PROTAC and target that results in ubiquitination and degradation permanently removes that target molecule from the functional pool, regardless of

future PROTAC fate. The pharmacological action endures until the cell resynthesizes the damaged protein, a process that might take hours to days depending on transcription, translation, and protein folding speeds.

This event-driven mechanism offers several theoretical and practical advantages:

Prolonged Duration of Action: Once a target protein is destroyed, cellular resynthesis is necessary to restore function. For proteins with slow turnover rates-such as transcription factors with half-lives of 24-48 hours-this provides a pharmacodynamic impact that extends much beyond drug exposure. Clinical investigations with ARV-471, for example, have showed prolonged ER degradation for days after drug delivery, permitting intermittent dosing regimes that would be difficult with inhibitors.

Sub-Stoichiometric Activity: PROTACs may be effective at concentrations below their target protein levels. While an inhibitor must attain >90% occupancy to block 90% of target activity, a PROTAC may destroy 90% of target protein while occupying just a portion of the entire target pool at any given point. This sub-stoichiometric activity possibly lessens off-target effects associated with high drug concentrations and minimizes drug-drug interactions induced by competition for metabolic enzymes or transporters.

Complete Functional Elimination: Unlike inhibitors that may leave residual protein activity-particularly for targets with high catalytic turnover or scaffolding roles-degradation destroys all protein functionalities. This comprises catalytic activity, protein-protein interactions, scaffolding functions, and nuclear localization signals. For oncogenic proteins that promote cancer via numerous routes, total removal may give better effectiveness than partial inhibition.

Overcoming Resistance Mutations: By destroying the protein totally rather than inhibiting a particular active site, PROTACs may overcome resistance mutations that limit inhibitor binding while retaining protein function. This has been established with BTK degraders, which preserve action against the C481S mutation that gives resistance to ibrutinib and other covalent BTK inhibitors.

Kinetic Complexity and Degradation Efficiency:-

However, the catalytic process also provides complexity that must be understood for rational medication design. The efficiency of deterioration relies on various kinetic parameters:

Ternary Complex Stability: The lifespan of the productive ternary complex dictates how many ubiquitin molecules may be transported before breakup. Longer-lived complexes often generate more widespread ubiquitination and more efficient breakdown.

Ubiquitination Rate: The intrinsic rate of ubiquitin transfer by the E2-E3 machinery varies between targets and cellular settings. Some proteins are "good substrates" that undergo quick polyubiquitination, whereas others resist ubiquitination despite ternary complex formation.

Deubiquitination Balance: Cellular deubiquitinases (DUBs) may remove ubiquitin chains, antagonizing degradation. The net degradation rate indicates the equilibrium between ubiquitination and deubiquitination activities.

Proteasome Accessibility: The vulnerability of the ubiquitinated protein to proteasomal unfolding and destruction varies dependent on protein stability, folding kinetics, and existence of proteasome-resistant regions.

Target Resynthesis Rate: The rate at which cells resynthesize destroyed proteins determines the steady-state protein level obtained under continuous PROTAC treatment. Rapidly turned-over proteins may need greater PROTAC concentrations or ongoing injection to sustain inhibition.

These kinetic considerations explain why certain high-affinity PROTACs fail to induce degradation while weaker binders succeed-the total degradation efficiency relies on the integrated activity of the complete catalytic cycle, not just initial binding affinity.

The Hook Effect: Concentration-Dependent Biphasic Activity:-

At high concentrations, PROTACs may display the "hook effect"-a phenomena where excessive PROTAC concentrations prevent rather than promote decomposition. This surprising behavior derives from the bivalent binding process and has substantial implications for dosage optimization and clinical development.

Mechanistic Basis of the Hook Effect:-

The hook effect arises when high PROTAC concentrations saturate both binding partners separately, generating non-productive binary complexes (PROTAC-POI and PROTAC-E3) rather than the productive ternary complex. At sufficiently high concentrations, the likelihood of a single PROTAC molecule simultaneously engaging both proteins become lower than the probability of building separate binary complexes with distinct PROTAC molecules.

Mathematically, the concentration of ternary complex [TC] may be stated as:-

$$[TC] = \frac{[PROTAC][POI][E3]}{(Kd1 \times Kd2 / \alpha)}$$

Where K_{d1} and K_{d2} are the dissociation constants for PROTAC-POI and PROTAC-E3 binding, and α is the cooperativity factor. As [PROTAC] grows, the concentrations of binary complexes [PROTAC-POI] and [PROTAC-E3] increase linearly, whereas the concentration of free POI and free E3 accessible for ternary complex formation declines. Beyond an appropriate PROTAC concentration, the synthesis of binary complexes outcompetes ternary complex formation, resulting to decreased breakdown.

Manifestations and Clinical Implications:-

The hook effect emerges as bell-shaped dose-response curves, with degradation efficiency rising at low concentrations, reaching a maximum at middle values, and dropping at high concentrations. Unlike conventional inhibitors where effectiveness normally rises monotonically with dosage, PROTACs may demonstrate optimum action within a small concentration window.

This phenomenon has numerous major therapeutic implications:-

Dosage Optimization: Clinical dosage selection must determine the concentration range that optimizes degradation while avoiding the hook effect. This needs thorough pharmacokinetic-pharmacodynamic modeling to ensure that trough concentrations stay above the threshold for efficient degradation while peak concentrations do not approach the hook effect zone.

Formulation Considerations: Sustained-release formulations that flatten plasma concentration-time profiles may be preferred to immediate-release formulations that create high peak concentrations. Conversely, pulsatile administration that maintains concentrations within the optimum window may boost effectiveness.

Therapeutic Index: The hook effect may actually offer a built-in safety mechanism, reducing toxicity at supratherapeutic levels. However, it also complicates dosage escalation in clinical studies, since greater doses may paradoxically impair effectiveness.

Interpatient Variability: Differences in drug metabolism, protein expression levels, and cellular permeability might change the optimum concentration window across individuals, thereby leading to varying therapeutic reactions.

Mitigation Strategies:-

Several ways have been tried to mitigate or eliminate the hook effect:

Molecular Glues: Monovalent degraders that act via a single binding site avoid the hook effect altogether by functioning through a separate mechanism. These chemicals stabilize protein-protein interactions between target and E3 ligase without needing simultaneous binding by a bivalent molecule.

Optimized Linker Design: Rigid linkers that pre-organize the PROTAC into ternary complex-compatible conformations may transfer the hook effect to higher concentrations by disfavoring binary complex buildup.

Covalent PROTACs: Reversible or irreversible covalent warheads that create stable conjugates with the target may inhibit binary complex dissociation, albeit this method compromises catalytic turnover.

Targeted Delivery: Antibody-drug conjugates or other targeted delivery methods that confine PROTAC concentration at the site of action while minimizing systemic exposure may keep local concentrations within the optimum window.

Cooperativity and Allosteric Communication:-

Beyond the hook effect, the development of ternary complexes presents chances for cooperative binding that might boost PROTAC effectiveness. Positive cooperativity—where binding to one protein improves binding to the second—can greatly boost ternary complex stability and degradation efficiency. Structural investigations have demonstrated that favorable protein-protein interactions between the POI and E3 ligase, mediated by complementary surfaces brought into contact by the PROTAC, may provide binding energy beyond that given by the PROTAC itself. These "protein-protein interaction cooperativity" effects may be evaluated and improved via structure-based design.

Conversely, negative cooperativity—where binding to one protein diminishes affinity for the second—can destabilize ternary complexes and impair degradation efficiency. Understanding and preventing negative cooperativity is a crucial feature of PROTAC optimization.

Comparison with Traditional Inhibition:-

To fully appreciate the mechanistic novelty of PROTACs, it is instructive to compare their mechanism with traditional small-molecule inhibition

Feature	Traditional Inhibitors	PROTAC Degraders
Mechanism	Block active site or binding interface	Induce protein destruction
Duration	Reversible; effect ends when drug clears	Persistent; requires protein resynthesis
Dosing	Requires sustained occupancy	Event-driven; lower concentrations possible
Target coverage	Occupies fraction of total pool	Eliminates entire protein pool
Resistance	Active site mutations reduce binding	Requires mutations preventing ubiquitination or degradation
Scaffolding	Preserved; may maintain oncogenic signaling	Eliminated; removes all protein functions
Catalytic efficiency	Stoichiometric (1:1)	Catalytic (1:many)

This comparison highlights why PROTACs represent not merely an incremental improvement but a fundamentally different therapeutic modality with distinct advantages and challenges.

Structural Design Principles and Structure-Activity Relationships:-

The rational design of PROTACs marks a paradigm change from conventional medicinal chemistry, when optimization focused exclusively on enhancing binding affinity to a specific target. PROTAC design demands simultaneous optimization of three unique molecular components-two protein-binding warheads and a connecting linker-while accounting for the emergent features of the ternary complex that ultimately determines degradation efficiency. This section presents a detailed review of the structural principles driving PROTAC function, the unique structure-activity connections that separate degraders from inhibitors, and the new computational tools allowing rational degrader design.

Warhead Selection: Beyond Affinity to Ternary Complex Compatibility:-

The protein of interest (POI)-targeting warhead serves as the basis upon which the whole PROTAC molecule is formed. While intuition may predict that high-affinity inhibitors would naturally translate into effective PROTAC warheads, significant empirical data has demonstrated that the structure-activity connections determining PROTAC effectiveness diverge fundamentally from those of occupancy-based inhibition.

The Warhead-PROTAC Activity Disconnect:-

Traditional medicinal chemistry optimization tries to increase binding affinity (usually represented as K_i or K_d) and residence duration to guarantee prolonged target occupancy. For PROTACs, however, the connection between warhead affinity and degrading efficiency is non-linear and frequently paradoxical. Several landmark studies have proven that warheads with intermediate affinity ($K_d \sim 100$ nM to 1 μ M) may create PROTACs with greater degrading activity compared to those obtained from picomolar inhibitors. This seeming contradiction emerges because PROTAC effectiveness relies not on binary binding affinity but on the creation of a productive ternary complex. An very high-affinity warhead may bind the POI so firmly that it precludes the conformational changes essential for effective E3 ligase recruitment. Conversely, a moderate-affinity warhead may enable dynamic sampling of conformations that support productive ternary complex geometry. Furthermore, highly tight binding may lead to "binary complex accumulation," where the PROTAC stays firmly attached to the POI without activating the E3 ligase, thus sequestering the PROTAC and lowering catalytic efficiency.

The therapeutic importance of this approach is profound: it permits the creation of PROTACs targeting proteins for which only weak or moderate binders exist. Proteins without deep, well-defined binding pockets-historically termed

"undruggable" by conventional standards-may be susceptible to PROTAC-mediated destruction employing fragment-sized warheads or allosteric binders that would be ineffectual as inhibitors.

Binding Site Topology and Ubiquitination Accessibility:-

Perhaps the most crucial warhead selection factor is the location of surface-accessible lysine residues relative to the binding site. The E3 ligase recruited by the PROTAC must be positioned within effective ubiquitination range of the target protein-typically within 20-50 Å of lysine residues that may act as ubiquitin acceptor sites. Crystal structures of productive ternary complexes consistently demonstrate that the E3 active site is positioned to permit direct ubiquitin transfer to accessible lysines on the POI surface.

This requirement imposes important constraints on warhead selection:-

Surface Exposure: The optimal binding location arranges the POI so that the PROTAC attachment point (exit vector) extends toward the solvent-exposed surface, enabling the linker and E3 ligase to project outward without steric conflicts.

Lysine Proximity: Regions of the POI high in surface lysines-particularly those in flexible loops or disordered regions-are favored. Conversely, binding sites buried inside the protein core or far from lysine residues may provide inefficient PROTACs despite good binding affinity.

Conformational Dynamics: Warheads binding to flexible areas may permit "ubiquitin-compatible" conformations that stiff inhibitors cannot reach. This explains why certain allosteric binders produce great PROTAC warheads despite limited affinity.

The relevance of lysine accessibility has been shown by thorough research of BET bromodomain degraders. While JQ1 and similar bromodomain inhibitors attach inside conserved acetyl-lysine recognition pockets, the generated PROTACs situate the recruited E3 ligase near to surface lysines on the bromodomain surface, permitting effective ubiquitination. Mutagenesis investigations have revealed that removal of these proximal lysines abolishes degradation without altering binding, underlining the contrast between occupancy and degradability.

Exit Vector Geometry and Linker Attachment Points:-

The exit vector-the exact atom or place on the warhead where the linker attaches-represents a significant but largely overlooked determinant of PROTAC activity. The three-dimensional trajectory of the escape vector defines how the linker extends from the POI-binding warhead and eventually affects the shape of the ternary complex.

Crystallographic investigations of ternary compounds have shown numerous principles regulating exit vector selection:

Vector Directionality: The exit vector should project away from the POI surface into solvent, avoiding collisions with the protein structure. Warheads with several possible attachment locations enable improvement of vector directionality via positional scanning.

Distance to Surface: Exit vectors positioned closer to the protein surface may need longer linkers to bridge to the E3 ligase, perhaps imparting flexibility that lowers ternary complex stability. Conversely, exit vectors reaching deeper from the surface may permit more compact, stiff linkers.

Rotational Freedom: Exit vectors with rotational flexibility enable the linker to sample conformations that enhance E3 ligase interaction. Rigid attachment points may confine the system to suboptimal geometries.

The optimization of exit vectors frequently involves considerable synthetic chemistry to develop positional isomers-analogs with linker attachments at various places around the warhead scaffold. Studies of BTK degraders, for example, have showed that shifting the linker attachment from the para- to meta-position on a phenyl ring may drastically modify degradation efficiency by altering the trajectory of E3 ligase recruitment.

Warhead Classes and Representative Examples:-

The PROTAC field has leveraged diverse warhead chemistries, each presenting distinct advantages and challenges:

Kinase Inhibitors as Warheads: The vast toolset of ATP-competitive kinase inhibitors has supplied several PROTAC warheads. Compounds such as dasatinib (BCR-ABL/SRC), foretinib (MET), and BI-2536 (PLK1) have been effectively turned into degraders. Kinase inhibitors are especially interesting because they frequently bind with well-defined geometries and documented SAR, allowing rational PROTAC design. However, the substantial sequence conservation of ATP-binding sites may restrict selectivity, and the active site placement may not always arrange the exit vector ideally for ubiquitination.

BET Bromodomain Inhibitors: JQ1, I-BET762, and similar BET inhibitors have been widely exploited as PROTAC warheads owing to their well-characterized binding mechanisms and the therapeutic relevance of BRD4 degradation. The tetrahydroquinoline and triazolodiazepine scaffolds allow various exit vector possibilities,

enabling substantial SAR investigation. BET-targeting PROTACs have provided some of the most effective and selective degraders recorded, including MZ1 (BRD4-selective) and ARV-771 (pan-BET).

Nuclear Hormone Receptor Ligands: Antagonists of the androgen receptor (AR) and estrogen receptor (ER) have been effectively turned into PROTAC warheads. Unlike kinase inhibitors that bind catalytic regions, nuclear receptor ligands engage allosteric pockets that modify receptor conformation. The clinical success of ARV-110 and ARV-471 illustrates that competitive antagonists may serve as effective warheads, however the huge size of these compounds offers synthesis problems.

Epigenetic Reader Inhibitors: Beyond BET bromodomains, inhibitors of various epigenetic readers-including chromatin reader domains, histone methyltransferases, and demethylases-are increasingly being studied as PROTAC warheads. The modular structure of epigenetic regulatory complexes affords several possible ubiquitination sites, albeit the nuclear localization of these targets needs cell-permeable PROTACs capable of nuclear entrance.

Covalent Warheads: Recent breakthroughs have examined covalent kinase inhibitors and other electrophilic warheads for PROTAC development. Covalent warheads have the benefit of irreversible target engagement, perhaps permitting lower PROTAC concentrations and longer duration of action. However, the irreversibility raises concerns regarding off-target reactivity and the possibility for immunogenicity. Electrophilic warheads targeting cysteine residues-such as those discovered in BTK, EGFR, and KRAS-have shown particular promise.

Fragment-Based Warheads: For problematic targets lacking powerful inhibitors, fragment-sized warheads (MW <300 Da) found by fragment screening are being examined. While individual fragments may bind with millimolar affinity, their modest size permits significant linker optimization and may offer access to cryptic binding locations. This method has been effectively applied to transcription factors and protein-protein interaction targets.

Residence Time and Binding Kinetics:-

While equilibrium binding affinity (K_d) offers a handy measure for warhead assessment, recent research shows that binding kinetics-particularly dissociation rate (k_{off}) and residence time ($\tau = 1/k_{off}$)-may be more predictive of PROTAC effectiveness. Warheads with prolonged residence durations may generate more stable ternary complexes, improving the efficacy of ubiquitin transfer. However, the link is complex: too lengthy residence durations may impede PROTAC recycling, limiting catalytic efficiency. The ideal residence duration presumably varies on the individual target, E3 ligase, and cellular environment. Some research imply that "medium" residence durations (minutes to hours) may be preferable to extremely lengthy residence times (days), permitting productive ternary complex development while allowing PROTAC turnover. This kinetic approach has prompted study in "reversible covalent" warheads that combine the stability of covalent attachment with the reversibility essential for catalytic PROTAC action. Warheads producing hemithioacetal or boronate ester linkages with target nucleophiles are being examined as possibly best compromises.

Computational Approaches to Warhead Selection:-

Computational techniques are increasingly supporting the sensible choosing of warheads:-

Molecular Docking: Docking simulations are able to discover escape vectors that project toward accessible lysines and anticipate warhead binding poses. Nevertheless, the induced fit and conformational changes connected to PROTAC binding are often missed by conventional docking techniques.

Molecular Dynamics Simulations: Warhead-bound POIs' dynamic behavior may be captured by long-timescale MD simulations, which show transitory conformations that disclose lysines capable of ubiquitination. The choice of warheads that stabilize "degradable" conformations may be influenced by these simulations.

Machine Learning algorithms: These algorithms, which have been trained on expanding datasets of PROTAC structures and activity data, are able to forecast the appropriateness of warheads for certain targets. Predictive methods integrate features such as warhead physicochemical characteristics, lysine accessibility, and binding site shape.

Proteome-Wide Screening: Chemoproteomic technologies allow for the objective discovery of warhead binding sites across the proteome, exposing unanticipated targets that might be off-target liabilities or PROTAC substrates.

Warhead Optimization Strategies:-

Iterative cycles are often used to optimize warheads for PROTAC applications:-

Initial Hit Identification: Initial warheads are assessed for binding affinity and cellular permeability, beginning with known inhibitors, fragments, or computationally anticipated binders.

Exit Vector Scanning: Positions that provide useful ternary complex geometries are found by methodically varying the linker attachment locations around the warhead scaffold. This often calls for the synthesis of ten to twenty positional isomers.

Affinity tuning: Medicinal chemistry optimization modifies affinity into the "sweet spot" for degradation (usually 10 nM–1 μ M) if initial warheads attach too firmly or too weakly. This might entail changing substituents that have an impact on binding without changing the exit vector.

Enhancement of Selectivity: Warheads that are selective for certain isoforms or mutants over related proteins are given priority, especially for kinase and bromodomain targets that include many family members.

Physicochemical Optimization: Given that linker and E3 ligase ligand attachment may further modify these characteristics, warheads are optimized for solubility, metabolic stability, and cell permeability.

E3 Ligase Ligands: Expanding the Recruitment Toolkit:-

While warhead selection determines which protein is targeted, the choice of E3 ligase ligand profoundly influences degradation efficiency, selectivity, and therapeutic index. The E3 ligase determines the cellular context dependence of PROTAC activity, as different tissues express E3 ligases at varying levels.

Cereblon (CRBN) Ligands: The Immunomodulatory Drug Platform:-

The immunomodulatory medicines (IMiDs) thalidomide, lenalidomide, and pomalidomide served as the first clinically proven E3 ligase ligands for PROTAC development. These glutarimide-containing drugs bind to cereblon's substrate receptor domain, which is part of the CRL4^{CRBN} E3 ubiquitin ligase complex.

Structural Features: The glutarimide moiety is required for CRBN binding, since it occupies a hydrophobic pocket that ordinarily holds substrate degrons. The phthalimide or similar aromatic system extends into a groove that defines substrate specificity.

Advantages: CRBN ligands have various benefits, including oral bioavailability, excellent physicochemical qualities, and known safety profiles based on decades of clinical usage in multiple myeloma. The tiny size of glutarimide-based ligands (MW ~250 Da) reduces the molecular weight load of the whole PROTAC.

Limitations: CRBN-based PROTACs may activate neo-substrate degradation proteins, which acquire degrons after binding to the drug-CRBN combination. This mechanism underpins both the therapeutic and teratogenic properties of IMiDs. Furthermore, CRBN expression varies amongst organs, possibly limiting effectiveness in CRBN-deficient environments.

Next-Generation CRBN Ligands: Recent research has attempted to expand CRBN ligands beyond the glutarimide scaffold. Cyclic imides, spirocyclic derivatives, and non-glutarimide binders are being investigated to minimize neo-substrate liabilities while retaining CRBN recruitment.

Von Hippel-Lindau (VHL) Ligands: High-Affinity Alternatives:-

The VHL substrate receptor, part of the CRL2^{VHL} complex, recognizes hydroxylated hypoxia-inducible factor (HIF) peptides under normoxic conditions. Peptidomimetic VHL ligands developed by the Ciulli laboratory and others have provided potent, selective tools for PROTAC development.

VH032 and Analogs: The hydroxyproline-containing ligand VH032 (K_d ~185 nM) and its optimized variants (VH101, VH298) bind VHL with high affinity via hydrogen bonding and hydrophobic interactions. Crystal structures have characterized the binding mode, allowing for reasonable optimization.

Advantages: VHL-based PROTACs often have better potency and more predictable degradation profiles than their CRBN-based competitors. VHL expression is ubiquitous, resulting in extensive tissue coverage. The well-defined binding mode simplifies structure-based design.

Limitations: VHL ligands are bigger and more polar than CRBN ligands, which contributes to their "beyond Rule of Five" features. Furthermore, VHL is a tumor suppressor, and persistent VHL sequestration by PROTACs has raised concerns about its possible oncogenic consequences.

MDM2 Ligands: Dual-Function Degradables:-

Nutlin-3a and similar cis-imidazoline compounds bind MDM2, inhibiting its interaction with p53 and so activating p53-dependent transcription. When integrated with PROTACs, MDM2 ligands provide the fascinating prospect of dual mechanism: degrading the POI while concurrently activating p53 tumor suppressor activity.

Structural Features: Nutlins inhabit the p53-binding pocket of MDM2, mimicking critical p53 residues. The chlorophenyl and ethoxy substituents give escape vectors for linker attachment.

Applications: MDM2-based PROTACs have been created targeting AR, BRD4, and other oncogenic proteins. The dual approach may give improved anti-tumor action, especially in p53-wildtype malignancies.

Challenges: MDM2 is typically amplified or overexpressed in malignancies, perhaps needing high PROTAC concentrations to compete with endogenous MDM2 interactions. Additionally, MDM2 suppression might generate p53-dependent toxicities that may narrow the therapeutic window.

cIAP Ligands: Exploiting the IAP Antagonists:-

Cellular inhibitor of apoptosis proteins (cIAP1/2) are bound by bestatin methyl ester and similar prional changes that activate the E3 ligase activity. This adds an extra layer of control.

Applications:cIAP-based PROTACs have demonstrated value for degrading proteins involved in cell survival and NF- κ B activation. The unique process may allow degradation of substrates resistant to conventional E3 ligases. Substances, which facilitates their auto-ubiquitination and destruction. In order to construct PROTAC, these ligands have been repurposed as E3 recruiters.

Mechanism:cIAP ligands cause conformational changes that activate the E3 ligase activity, in contrast to CRBN and VHL ligands, which just recruit the E3 ligase. This adds another level of control.

Applications:cIAP-based PROTACs have shown effectiveness in breaking down proteins related to NF- κ B signaling and cell viability. Degradation of substrates resistant to other E3 ligases may be made possible by the special mechanism.

Emerging E3 Ligase Ligands:-

An enormous unexplored resource for PROTAC creation is the approximately 600 E3 ligases encoded by the human genome:

DCAF1, DCAF15, and DCAF16: These DDB1-CUL4 related factors' ligands are becoming viable substitutes for CRBN, providing unique substrate specificities and perhaps lower neo-substrate liabilities.

RNF114, RNF4: Selective degradation in certain cancer types may be made possible by RING finger ligases with limited tissue expression.

Fem1B: Fem1B provides a unique mechanism for substrate recognition and was recently shown to be a target for covalent ligands.

RNF43, SIAH1, and KLHDC2: For specific uses, such as extracellular and membrane protein breakdown, other E3 ligases with distinct cellular localizations and substrate preferences are being investigated.

One of the most active areas of PROTAC research is the development of the E3 ligase ligand toolbox, which has the potential to significantly increase the range of targetable proteins while enhancing selectivity and lowering toxicity.

Linker Design: The Molecular Connector That Defines Geometry:-

The linker is the most unique and frequently most demanding component of PROTAC design. Unlike classical medicinal chemistry where linkers just join pharmacophores, PROTAC linkers actively engage in ternary complex formation and may drastically alter cellular permeability, metabolic stability, and degradation efficiency.

Linker Length and the Distance Constraint:-

The major role of the linker is to bridge the gap between the POI-bound warhead and the recruited E3 ligase. Crystallographic investigations of ternary complexes have showed that effective PROTACs often span 20-50 Å between the two protein surfaces.

Short Linkers (5-15 atoms): May fail to cross the requisite distance, inhibiting ternary complex formation or imposing undesirable protein-protein interactions. However, short linkers may increase cell permeability and metabolic stability.

Medium Linkers (15-25 atoms): Often ideal for various POI-E3 combinations, offering adequate length for geometric flexibility without undue entropic cost.

Long Linkers (>25 atoms): Enable ternary complex synthesis for distant binding sites but may suffer from entropic penalties, diminished cell permeability, and metabolic lability. Very lengthy linkers may also boost the hook effect at lesser doses.

The ideal linker length is target-dependent and must be experimentally established. Systematic length variation-synthesizing homologous series with 2, 3, 4, and 5 PEG units, for example-is a typical optimization method.

Linker Composition: Balancing Flexibility and Rigidity:-**Linker chemistry substantially alters PROTAC behavior:-**

Polyethylene Glycol (PEG) Linkers: PEG chains give flexibility, water solubility, and resistance to proteolytic cleavage. PEG-based linkers have been widely exploited and are well-tolerated pharmacologically. However, PEG flexibility may lead to entropic costs and may not pre-organize the molecule for productive ternary complex formation.

Alkyl Linkers: Simple alkyl chains provide hydrophobicity and membrane permeability but may suffer from metabolic oxidation and diminished water solubility.

Rigid Spacers: Rigid linkers integrating aromatic rings, triple bonds, or cyclic motifs may pre-organize the PROTAC into conformations conducive for ternary complex formation. Triazole linkers produced by click chemistry have been especially effective, delivering stiffness while retaining synthetic accessibility.

Cleavable Linkers: Self-immolative or enzyme-cleavable linkers facilitate PROTAC activation in particular cellular situations. Esterase-cleavable linkers, for example, may release active degraders intracellularly after systemic injection.

Conformational Control and Chameleonic Behavior:-

Recent advancements have stressed the relevance of conformational control in linker design. PROTACs must adopt unique conformations in different environments:

Extracellular/Membrane Environment: In aqueous extracellular fluid and during membrane transit, PROTACs should assume compact, generally non-polar conformations to optimize permeability.

Intracellular Environment: In the cytosol, PROTACs must sample prolonged conformations that permit simultaneous engagement of POI and E3 ligase.

Ternary Complex: In the productive ternary complex, the linker adopts a particular shape that places the E3 ligase ideally for ubiquitin transfer.

This "chameleonic" characteristic may be produced by careful linker design. Intramolecular hydrogen bond donors and acceptors may preserve compact conformations during membrane transit, whereas these bonds break in aqueous conditions to enable prolonged conformations. Macrocyclic linkers that confine the molecule into certain geometries have showed promise in enhancing both permeability and degradation efficiency.

Linker Attachment Chemistry:-

PROTAC stability and synthetic accessibility are influenced by the chemistry that binds the linker to warheads and E3 ligands:

Amide Bonds: Used extensively, amide bonds are metabolically resistant and stable, but they must be positioned carefully to prevent interfering with warhead binding.

Triazoles: Rigidity and metabolic stability are provided by triazoles, which are created via azide-alkyne cycloaddition (click chemistry) catalyzed by copper. A common component of PROTAC linkers is the 1,4-disubstituted triazole.

Ethers and Thioethers: Although thioethers may be converted to sulfoxides, ethers and thioethers provide flexibility and metabolic stability.

Carbamates and Ureas: Ureas and carbamates both provide metabolic stability and the ability to form hydrogen bonds, with carbamates offering more synthetic flexibility.

Carbon-Carbon Bonds: Although they need more intricate synthetic pathways, direct C-C links provide the highest level of stability.

Structure-Activity Relationships Unique to PROTACs:-

The SAR governing PROTAC activity differs fundamentally from traditional small molecules, requiring new conceptual frameworks and experimental approaches.

Cooperativity and Ternary Complex Stability:-

A cooperativity parameter (α) that measures whether PROTAC binding to one protein increases (positive cooperativity, $\alpha > 1$) or decreases (negative cooperativity, $\alpha < 1$) binding to the second protein may be used to describe the development of the ternary complex.

Positive Cooperativity: The ternary complex is stabilized more than would be predicted from separate binding events when PROTAC binding to the POI causes conformational modifications that improve E3 ligase recruitment, or vice versa. This is very conducive to deterioration.

Negative Cooperativity: Degradation efficiency is reduced when binding to one protein sterically or electrostatically discourages engagement of the second protein.

Neutral Cooperativity: Independent binding events without allosteric communication are known as neutral cooperativity. In the lack of structural knowledge, this is the starting point.

Biophysical analysis of ternary complexes employing methods like isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), and FRET-based assays is necessary to understand and optimize cooperativity. The best understanding of cooperative binding processes may be gained from the crystal structures of ternary complexes.

The Hook Effect and Dose-Response Complexity:-

Because of the hook effect, PROTACs may show bell-shaped dose-response curves, in contrast to conventional inhibitors, where effectiveness usually rises monotonically with concentration. Instead of creating the productive ternary complex, PROTACs saturate both binding partners individually at high concentrations, resulting in non-productive binary complexes. This phenomena has significant effects on SAR.

Potency vs. Efficacy: The concentration of half-maximum degradation (DC50) may be different from the concentration of maximal degradation (DCmax). Suboptimal compounds may result from optimizing for DC50 without taking DCmax into account.

Therapeutic Window: By reducing toxicity at supratherapeutic dosages, the hook effect may actually provide an inherent safety mechanism. But in clinical trials, it also makes dosage selection more difficult.

Considerations for Formulation: Immediate-release formulations that result in high peak concentrations may be inferior to sustained-release formulations that keep PROTAC concentrations within the ideal window.

Cellular Permeability and the "Beyond Rule of Five" Paradox:-

Lipinski's Rule of Five, which forecasts oral bioavailability for small compounds, is broken by the majority of successful PROTACs. Theoretically, PROTACs should have low absorption and permeability due to their large polar surface areas, many hydrogen bond donors and acceptors, and molecular weights of 700-1200 Da.

However, a lot of clinically developed PROTACs have a respectable oral bioavailability. The following factors have been linked to this "beyond Rule of Five" behavior:

Chameleonic Conformations: During membrane transit, PROTACs may take on intramolecularly hydrogen-bonded conformations that increase lipophilicity and conceal polarity.

Active Transport: Despite having undesirable physicochemical characteristics, several PROTACs may be substrates for uptake transporters such OATP or ENT family proteins, allowing cellular entrance.

Endocytosis: Endocytic uptake processes may be triggered by high local concentrations or certain chemical characteristics.

Metabolic Stability: Compared to conventional small molecules, PROTACs may have distinct metabolic profiles, with delayed clearance allowing for prolonged exposure.

Research on understanding and improving these "beyond Rule of Five" features is ongoing. Among the tactics are:

Macrocyclization: By limiting PROTACs to cyclic structures, ternary complex compatibility is maintained while polar surface area is decreased and permeability is enhanced.

Prodrug Approaches: Esterases or other enzymes may release active PROTAC intracellularly, while masking polar groups with cleavable protecting groups can enhance permeability.

Formulation Optimization: Complexation agents, lipid-based delivery systems, and nanoparticle formulations may improve tissue distribution and oral absorption.

Biophysical and Structural Characterization:-

Rational PROTAC design relies heavily on structural and biophysical characterization of binary and ternary complexes.

X-Ray Crystallography and Cryo-EM:-

Atomic-resolution understanding of the PROTAC mechanism is provided by the crystal structures of ternary complexes.

Ternary Complex Structures: The exact geometry of induced protein-protein interactions, linker conformations, and ubiquitination-competent lysine placement are revealed by the structures of POI-PROTAC-E3 complexes.

Binary Complex References: PROTAC design and computational modeling begin with the crystal structures of the warhead-POI and E3 ligand-E3 complexes.

Challenges: Because ternary complexes are transitory and need simultaneous binding of all three components, they may be challenging to crystallize. Larger ternary complexes that are resistant to crystallization are increasingly being treated using cryo-EM.

Nuclear Magnetic Resonance (NMR) Spectroscopy:-

NMR provides unique capabilities for studying PROTAC complexes

Solution-State Dynamics: NMR can capture the dynamic behavior of ternary complexes in solution, revealing conformational ensembles that static crystal structures miss.

Weak Interactions: NMR can detect weak or transient protein-protein interactions that may be important for initial ternary complex formation.

Ligand-Based Methods: Saturation transfer difference (STD) NMR and related techniques can characterize PROTAC binding even when protein structures are unavailable.

Computational Modeling and Machine Learning:-

Computational approaches are increasingly important for PROTAC design

Ternary Complex Prediction: Methods such as PROsettaC, AlphaFold-based approaches, and molecular docking pipelines can predict ternary complex structures, guiding linker optimization.

Machine Learning Models: Neural networks trained on PROTAC activity data can predict degradation efficiency from chemical structure, enabling virtual screening and optimization.

Molecular Dynamics: Long-timescale simulations can capture the conformational dynamics of PROTACs and their complexes, revealing transient states important for activity.

Synthetic Strategies and Scalability:-

The synthesis of PROTACs presents unique challenges due to their size and structural complexity.

Convergent vs. Linear Synthesis:-

Convergent Approaches: Warhead and E3 ligand are manufactured independently before being linked in the latter stages. This allows for late-stage diversification and is often favored for efficiency.

Linear Synthesis: Stepwise construction from one end is known as a linear approach. When orthogonal protective group techniques are needed, it can be essential.

Click Chemistry and Modular Assembly:-

Copper-catalyzed azide-alkyne cycloaddition (CuAAC) has become a mainstay of PROTAC synthesis, enabling efficient linker formation and modular assembly of diverse PROTAC libraries from prefabricated warhead and E3 ligand building blocks.

Strain-Promoted Click Chemistry: Copper-free variants using strained alkynes enable bioorthogonal PROTAC synthesis and in-cell applications.

Solid-Phase Synthesis:-

For peptide-containing PROTACs or those requiring extensive purification, solid-phase synthesis offers advantages in purity and handling.

Manufacturing Considerations:-

Manufacturing scalability becomes crucial as PROTACs move toward clinical development and commercialization: Process Chemistry: Specialized knowledge of process chemistry is needed to provide scalable, economical synthesis pathways for complicated PROTACs. Purification: PROTACs' huge size and polarity may make purification more difficult. Crystallization, preparative HPLC, and reverse-phase chromatography are often used. Formulation: Complex formulation development is often needed to provide adequate water solubility and stability for parenteral or oral administration.

Clinical Advances and the Evolving Therapeutic Landscape:-

The First Wave: ARV-110 and ARV-471:-

The clinical validation of PROTAC technology came with the development of ARV-110 and ARV-471 by Arvinas, in collaboration with Pfizer.

ARV-110 (Bavdegalutamide): The first PROTAC to get into clinical trials was ARV-110, which targets the androgen receptor (AR) for metastatic castration-resistant prostate cancer (mCRPC). Preclinical research showed inhibition of AR-associated gene expression and >90% AR degradation in prostate tumor xenografts. According to phase I data, ARV-110 was well tolerated at dosages up to 420 mg, and tumor samples revealed indications of AR degradation. However, patients who had received extensive pretreatment showed minimal clinical effectiveness, which prompted a strategy shift toward earlier treatment lines and combination methods.

ARV-471 (Vepdegestrant): ARV-471, the flagship PROTAC program, targets the estrogen receptor (ER) for ER+/HER2- breast cancer. Phase I findings showed significant clinical benefit rates in individuals with extensive pretreatment, as well as strong ER degradation that was better than fulvestrant, the current standard-of-care ER degrader. A significant advancement in PROTAC development is the VERITAC-2 Phase III study, which compares fulvestrant with vepdegestrant in individuals with ESR1-mutated illness. "A major milestone in targeted protein degradation was achieved on May 1, 2026, when the U.S. Food and Drug Administration (FDA) approved

vepdegestrant (ARV-471), developed jointly by Arvinas and Pfizer and marketed under the brand name VEPPANU, for the treatment of adults with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer.

The Expanding Clinical Pipeline:-

As of 2024-2025, approximately 30 PROTACs have entered clinical trials, with some proceeding to Phase II and Phase III studies: -

BTK Degraders: Multiple projects target Bruton's tyrosine kinase (BTK) for B-cell malignancies, including BGB-16673 (BeiGene), NX-2127 (Nurix), and HSK29116. These degraders provide potential benefits over covalent BTK inhibitors by targeting both wild-type and C481S mutant BTK, which imparts resistance to ibrutinib.

KRAS Degraders: Given the problems of blocking mutant KRAS, PROTAC methods targeting multiple KRAS mutants are in early clinical development, including ASP3082 (Astellas).

IAP and BCL-2 Degraders: Targeting anti-apoptotic proteins, degraders such as KT-253 (Kymera) targeting MDM2 are being studied in solid tumors and hematologic malignancies.

Epigenetic Target Degraders: PROTACs targeting BET bromodomains (ARV-825, ARV-771), EZH2, and HDAC6 have demonstrated promising preclinical action and are heading toward clinical investigation.

Regulatory Considerations and Approval Pathways:-

The approval of vepdegestrant has created key precedents for PROTAC regulatory routes. Key factors include:

Biomarker-Driven Development: The approval was especially for ESR1-mutated breast cancer, underlining the need of companion diagnostics and patient stratification. **Pharmacodynamic Endpoints:** Unlike conventional cancer treatments where tumor shrinking is the major objective, PROTAC development has added target degradation as a pharmacodynamic biomarker, allowing more efficient dosage selection and proof-of-mechanism confirmation. **Safety Monitoring:** The catalytic mechanism of PROTACs presents theoretical concerns concerning off-target degradation. Regulatory authorities have stressed thorough proteome analysis to detect and monitor possible off-target effects.

Key Therapeutic Targets in Cancer:-

Nuclear Hormone Receptors: Validated Targets:-

The androgen receptor and estrogen receptor are attractive PROTAC targets because to their well-characterized ligand-binding domains, nuclear localization, and recognized involvement in prostate and breast cancer, respectively. The clinical success of ARV-110 and ARV-471 confirms this target class and has prompted research of new nuclear receptor degraders.

Androgen Receptor: Beyond ARV-110, several AR PROTACs are under development, including drugs targeting AR splice variations (such as AR-V7) that promote resistance to traditional AR antagonists.

Estrogen Receptor: The success of vepdegestrant has accelerated interest in next-generation ER degraders with better characteristics and combination potential with CDK4/6 and PI3K pathway inhibitors.

Kinases: Beyond Inhibition:-

Although kinases have been the most widely treated target class in cancer, acquired resistance is still a problem. PROTACs have a number of benefits:

Overcoming Resistance Mutations: Regardless of active site mutations that provide resistance to ATP-competitive inhibitors, PROTACs may eradicate kinase activity by breaking down the complete protein.

Eliminating Scaffold roles: Oncogenesis is encouraged by the non-catalytic scaffolding roles of several kinases. These functions are eliminated by PROTACs but not by inhibitors.

BTK, BCR-ABL, and EGFR: Degraders that target the kinases BTK, BCR-ABL, and EGFR are at different phases of research and show promise in overcoming resistance to well-established inhibitors.

Transcription Factors and Epigenetic Regulators:-

Perhaps the most fascinating use of PROTACs is in targeting transcription factors and epigenetic modulators-proteins that have been generally refractory to small-molecule inhibition.

BET Bromodomains: BRD4 and other BET family proteins are important dependencies in many malignancies. PROTACs such as ARV-771 and dBET6 have exhibited greater effectiveness than BET inhibitors in preclinical studies.

EZH2: The histone methyltransferase EZH2 induces proliferation in many malignancies. EZH2 degraders have showed potential in preclinical investigations, especially in small cell lung cancer models.

p53 Regulators: MDM2 and MDMX degraders give the combined advantage of removing negative regulators while activating p53 tumor suppressor activity.

Immunotherapy Targets:-

PROTACs are being explored to modulate the tumor immune microenvironment by degrading immune checkpoint proteins, cytokine receptors, and signaling molecules that suppress anti-tumor immunity. This represents a promising frontier for combining targeted protein degradation with immunotherapy approaches.

Challenges and Limitations:-**Pharmacokinetic and Formulation Challenges:-**

Despite the clinical effectiveness of vepdegestrant, the physicochemical features of PROTACs remain a substantial hurdle:

Oral Bioavailability: Many PROTACs display poor oral bioavailability owing to their large bulk and strong polarity. Strategies to overcome this include macrocyclization, prodrug techniques, and formulation improvement.

Tissue Distribution: Achieving therapeutic concentrations in solid tumors remains hard. The development of nano-PROTAC formulations and tumor-targeted delivery methods is an important field of study.

Blood-Brain Barrier Penetration: CNS-active PROTACs are especially problematic owing to the blood-brain barrier. This restricts the applicability of PROTACs in brain metastases and primary CNS cancers.

Resistance Mechanisms:-

As with other targeted medicines, resistance to PROTACs is developing as a clinical concern:

Target Mutations: Mutations in the POI that impair PROTAC binding while keeping protein function may give resistance. This has been found with BTK degraders in individuals with C481S mutations.

E3 Ligase Alterations: Downregulation or mutation of the recruited E3 ligase may disrupt PROTAC activity. CRISPR screening have revealed E3 ligase components as predictors of PROTAC sensitivity.

Proteasome Dysfunction: Alterations in proteasome subunits or overexpression of deubiquitinating enzymes may affect degradation efficiency.

Ternary Complex Disruption: Mutations that affect the protein-protein interaction between the POI and E3 ligase may inhibit productive ternary complex formation.

Off-Target Degradation and Toxicity:-**The catalytic nature of PROTACs raises concerns about off-target effects:-**

Neo-Substrate Degradation: Proteins that attach to the drug-CRBN complex and gain degrons may unintentionally be degraded by CRBN-recruiting PROTACs. Thalidomide teratogenicity is caused by this process, which calls for close observation.

Tissue-Specific E3 Expression: Different tissues have different patterns of E3 ligase expression, which affects the safety and effectiveness of PROTACs. In tissues with strong E3 expression, this may result in on-target toxicity.

Clinical Translation Challenges and Future Considerations:-

Although targeted protein degradation has rapidly evolved from an innovative concept to a clinically validated therapeutic strategy, several translational challenges continue to limit its widespread clinical application. Addressing these issues will be essential for the successful integration of PROTAC-based therapeutics into routine oncology practice. One of the major challenges is patient selection. The efficacy of PROTACs depends not only on target protein expression but also on the intracellular abundance and functionality of the recruited E3 ubiquitin ligase. Variability in the expression of E3 ligases such as cereblon (CRBN) and von Hippel-Lindau (VHL) across different tumor types and among individual patients may significantly influence therapeutic response. Consequently, future clinical studies should incorporate biomarker-driven patient stratification to identify individuals most likely to benefit from PROTAC therapy. Another important limitation is the absence of validated predictive biomarkers for monitoring treatment response. Unlike conventional small-molecule inhibitors, PROTACs induce degradation rather than transient inhibition of target proteins. Therefore, biomarkers capable of quantifying intracellular protein degradation, ubiquitination efficiency, and target resynthesis rates will be critical for optimizing treatment strategies and evaluating pharmacodynamic responses during clinical development.

Dose optimization also presents unique challenges. PROTACs exhibit concentration-dependent degradation kinetics characterized by the hook effect, where excessive drug concentrations reduce degradation efficiency by favoring the formation of non-productive binary complexes. This phenomenon complicates dose selection and highlights the need for comprehensive pharmacokinetic-pharmacodynamic modeling during clinical trials. Long-term safety remains incompletely understood. Although early clinical studies have demonstrated encouraging tolerability, prolonged degradation of essential cellular proteins may potentially disrupt physiological protein homeostasis. Furthermore, unintended degradation of off-target proteins, particularly with CRBN-recruiting degraders, may

contribute to unforeseen toxicities. Long-term follow-up studies will therefore be essential to establish the safety profile of these agents.

Manufacturing and formulation also represent significant barriers to commercialization. The large molecular size and structural complexity of PROTACs frequently result in poor aqueous solubility, limited oral bioavailability, and challenging synthetic routes. These characteristics increase manufacturing costs and complicate large-scale production compared with conventional small-molecule therapeutics.

Regulatory evaluation of PROTACs requires novel clinical endpoints beyond traditional efficacy measures. Since protein degradation represents a unique pharmacodynamic mechanism, regulatory agencies are increasingly emphasizing the importance of target degradation biomarkers, quantitative proteomic analyses, and mechanistic validation during clinical development. Future regulatory guidelines specifically addressing targeted protein degradation technologies will facilitate more efficient drug development and approval pathways.


Despite these challenges, continuous advances in medicinal chemistry, computational drug design, biomarker discovery, targeted drug delivery systems, and next-generation degrader technologies are expected to overcome many current limitations. As our understanding of induced protein degradation continues to expand, PROTACs are poised to become an integral component of precision oncology and personalized cancer therapy.

Major Clinical Challenges Limiting PROTAC Translation:-

Challenge	Clinical Impact	Possible Solutions
Poor oral bioavailability	Reduced systemic exposure	Prodrug design, nanoformulations
Large molecular size	Limited membrane permeability	Macrocyclization, linker optimization
Variable E3 ligase expression	Patient-dependent efficacy	Biomarker-guided therapy
Hook effect	Difficult dose optimization	PK/PD-guided dosing
Off-target degradation	Safety concerns	Highly selective warheads
Resistance mechanisms	Reduced therapeutic response	Novel E3 ligases and combination therapy
Manufacturing complexity	High production cost	Scalable synthetic routes

Emerging Targeted Protein Degradation Technologies:-

While PROTACs have dominated the TPD landscape, a diverse ecosystem of complementary technologies is emerging:



Expanding Landscape of Targeted Protein Degradation Technologies

Molecular Glues: The Monovalent Alternative:-

Molecular glues provide a chemically unique method to induced protein breakdown. Unlike bifunctional PROTACs, molecular glues are tiny, monovalent entities that stabilize protein-protein connections between an E3 ligase and a neo-substrate. Immunomodulatory medications (IMiDs) such as lenalidomide and pomalidomide work as molecular glues, guiding CRL4^{CRBN} to destroy transcription factors Ikaros and Aiolos. The identification of novel molecular glue mechanisms-such as the CC-90009-induced degradation of GSPT1-has extended the targetable proteome. Molecular glues provide benefits in oral bioavailability and synthetic accessibility, yet their development has traditionally depended on chance. Recent advancements in rational design and high-throughput screening are allowing more methodical molecular glue development.

Lysosome-Targeting Chimeras (LYTACs):-

The proteasome is restricted to intracellular proteins. LYTACs expand targeted degradation to extracellular and membrane-bound proteins by leveraging the endosome-lysosome route. LYTACs consist of a glycopolymer or antibody that binds cell surface lysosome-targeting receptors (such as the cation-independent mannose-6-phosphate receptor) coupled to a target-binding moiety. Upon binding, the LYTAC-target complex is internalized and transported to lysosomes for destruction. This permits the removal of growth factor receptors, immunological checkpoint proteins, and secreted substances that cause cancer development.

Autophagy-Targeting Chimeras (AUTACs and ATTECs):-

Autophagy-based methods provide an alternate breakdown pathway for proteins that avoid proteasomal degradation, such as protein aggregates, big complexes, and specific organelles.

ATTECs (Autophagosome-Tethering Compounds): Target proteins are tagged with K63-linked polyubiquitin chains or particular degradation tags (KFERQ-like motifs) by AUTACs (Autophagy-Targeting Chimeras), which attract the autophagy machinery.

ATTECs (Autophagosome-Tethering Compounds): Autophagosome-Tethering Compounds, or ATTECs, are tiny compounds that physically attach target proteins to LC3 on autophagosome membranes, allowing for lysosomal breakdown and engulfment. ATTECs may be used in cancer and have shown special potential in breaking down aggregates in neurological illnesses.

Antibody-Based Degraders:-**Several antibody-based formats extend PROTAC concepts:-**

AbTACs (Antibody-based PROTACs): Bispecific antibodies recruit membrane-bound E3 ligases (such as RNF43) to cell surface targets, inducing internalization and degradation.

DACs (Degradation-Antibody Conjugates): PROTACs conjugated to tumor-targeting antibodies enable selective delivery to cancer cells, potentially reducing systemic toxicity.

GlueTACs: These combine antibody targeting with molecular glue mechanisms for cell surface protein degradation.

8.5 RNA-PROTACs and Transcriptional Regulation

Emerging targeted protein degradation technologies are rapidly expanding beyond conventional protein elimination to encompass the regulation of RNA molecules and transcriptional machinery, thereby broadening the therapeutic landscape for diseases driven by previously undruggable targets. These next-generation induced-proximity approaches aim to modulate gene expression at multiple regulatory levels, offering greater precision and versatility than traditional small-molecule inhibitors. By targeting RNA transcripts or transcriptional regulators instead of mature proteins, these technologies have the potential to suppress oncogenic signaling at its source and overcome resistance mechanisms associated with protein-targeted therapies.

Ribonuclease-Targeting Chimeras (RiboTACs) represent an innovative class of heterobifunctional molecules designed to selectively degrade disease-associated RNA transcripts. Similar to the mechanism of proteolysis-targeting chimeras (PROTACs), RiboTACs function by inducing molecular proximity; however, instead of recruiting E3 ubiquitin ligases to proteins, they recruit endogenous ribonucleases such as RNase L to specific RNA molecules. A typical RiboTAC consists of an RNA-binding ligand connected through a chemical linker to an RNase-recruiting moiety. Upon binding the target RNA, the recruited ribonuclease catalyzes selective RNA degradation, thereby preventing translation into functional protein. This strategy enables the therapeutic targeting of non-coding RNAs, oncogenic messenger RNAs (mRNAs), fusion transcripts, and mutant RNA species that are difficult or impossible to inhibit using conventional protein-directed drugs. Because RNA degradation occurs upstream of protein synthesis, RiboTACs may provide more durable suppression of oncogenic pathways while reducing the likelihood of compensatory protein accumulation. Emerging preclinical studies have demonstrated promising activity against RNA targets involved in cancer, viral infections, and neurodegenerative disorders, highlighting the potential of RiboTACs as a novel therapeutic platform.

Another rapidly evolving strategy involves:

Transcriptional PROTACs (TRIMTACs and related transcription-targeting degraders), which are designed to modulate gene expression by recruiting transcriptional regulators or chromatin-remodeling complexes to specific genomic loci. Unlike classical PROTACs that promote degradation of existing proteins, transcriptional PROTACs interfere with the initiation or maintenance of gene transcription by directing epigenetic modifiers, transcriptional repressors, or degradation machinery toward oncogenic transcription factors and regulatory DNA elements. These molecules may recruit histone deacetylases (HDACs), DNA methyltransferases (DNMTs), Polycomb repressive complexes, or other chromatin-modifying proteins to induce long-lasting transcriptional silencing of cancer-promoting genes. Some approaches also utilize targeted degradation of transcription factors or RNA polymerase-associated proteins, thereby preventing continuous oncogene expression. Since many oncogenic drivers-including:

MYC, MYB, STAT3, β -catenin, and certain fusion transcription factors-have historically been considered "undruggable" due to the absence of suitable ligand-binding pockets, transcriptional PROTACs offer an attractive alternative by regulating their expression or destabilizing their transcriptional machinery rather than directly inhibiting protein function. Collectively, RiboTACs and transcriptional PROTACs represent the next frontier in induced-proximity therapeutics. By extending targeted degradation strategies from proteins to RNA molecules and transcriptional regulation, these technologies significantly expand the spectrum of druggable targets in cancer and other complex diseases. Continued advances in structural biology, RNA-targeting chemistry, epigenetic engineering, and delivery systems are expected to accelerate their translation from experimental platforms to clinical therapeutics, ultimately providing highly selective and durable approaches for precision medicine.

Future Perspectives and Research Directions:-

Expanding the Druggable Proteome:-

Targeted protein degradation using proteolysis-targeting chimeras (PROTACs) has fundamentally transformed the concept of druggability by enabling the elimination of proteins that were previously considered inaccessible to conventional small-molecule inhibitors. Unlike occupancy-driven therapeutics, which require high-affinity binding to enzymatic active sites, PROTACs function through event-driven pharmacology, inducing ubiquitination and subsequent proteasomal degradation of target proteins. This unique mechanism substantially broadens the spectrum of therapeutically accessible proteins, including transcription factors, scaffolding proteins, adaptor molecules, chromatin remodelers, and other non-enzymatic proteins that have historically been classified as "undruggable." Despite this remarkable progress, the full potential of PROTAC technology remains largely unexplored because current degraders utilize only a small fraction of the human ubiquitin–proteasome system.

The human genome encodes more than 600 E3 ubiquitin ligases, yet fewer than ten-including cereblon (CRBN), von Hippel–Lindau (VHL), MDM2, inhibitor of apoptosis proteins (IAPs), RNF114, and DCAF15-are routinely exploited for PROTAC development. Expanding the repertoire of recruitable E3 ligases represents one of the most promising avenues for future research. Systematic characterization of tissue-specific, cancer-specific, and inducible E3 ligases may enable the design of tumor-selective PROTACs capable of preferentially degrading oncogenic proteins within malignant tissues while minimizing degradation in healthy cells. Such tissue-restricted degradation strategies could significantly improve therapeutic selectivity, reduce systemic toxicity, and enhance the overall therapeutic index. Furthermore, different E3 ligases recognize distinct substrate conformations and degron motifs, allowing degradation of proteins that are not efficiently targeted by currently available CRBN- or VHL-based PROTACs. Continued exploration of novel E3 ligases, together with advances in structural biology and ligand discovery, is therefore expected to considerably expand the druggable proteome and facilitate the development of highly selective precision oncology therapeutics.

Rational Design and Artificial Intelligence-Driven Discovery:-

The development and optimization of PROTACs have typically depended on iterative medicinal chemistry and extensive experimental screening, approaches that are both time-consuming and resource-intensive. Recent breakthroughs in artificial intelligence (AI), machine learning (ML), and computational structural biology are altering this paradigm by allowing logical, data-driven PROTAC design. These computational technologies facilitate prediction of productive ternary complex formation, optimization of linker architecture, identification of suitable E3 ligases, and evaluation of pharmacokinetic and pharmacodynamic properties before compound synthesis, thereby significantly accelerating drug discovery while reducing development costs.

Formation of a stable protein of interest (POI)-PROTAC-E3 ligase ternary complex is the key determinant of degradation efficiency. Deep learning algorithms trained on structural datasets, molecular dynamics simulations, and protein-protein interaction networks can accurately predict the stability, orientation, cooperativity, and ubiquitination potential of ternary complexes, enabling researchers to prioritize the most promising molecular designs for experimental validation. Artificial intelligence is also redefining linker optimization, a vital component that regulates molecular flexibility, cellular permeability, degradation potency, and overall pharmacological effectiveness. Generative machine learning algorithms can create linker scaffolds with improved physicochemical qualities while decreasing molecular weight and boosting metabolic stability. In addition, AI-driven proteome-wide investigations may uncover possible off-target degradation processes, forecast toxicity profiles, analyze resistance mechanisms, and aid in biomarker identification. Integration of AlphaFold structure prediction, virtual screening, molecular docking, and multi-omics datasets is predicted to greatly promote the rational design of next-generation PROTACs, allowing the creation of safer, more selective, and more effective targeted degraders.

Combination Therapies and Treatment Sequencing:-

Although PROTACs have exhibited substantial promise as monotherapies, their greatest therapeutic effect is anticipated to emerge via reasonable combination methods with established anticancer medicines. Cancer is characterized by complicated signaling networks and high molecular heterogeneity, enabling tumor cells to activate compensatory mechanisms after targeted protein degradation. Consequently, combination treatments capable of concurrently targeting several oncogenic processes may elicit more sustained responses while minimizing the establishment of therapeutic resistance.

One interesting technique includes combining PROTACs with conventional small-molecule inhibitors targeting the same or comparable signaling pathways. Such combinations may offer both rapid enzymatic inhibition and prolonged clearance of disease-driving proteins, so delivering more thorough suppression of oncogenic signaling than either modality alone. Sequential treatment regimens may potentially delay or prevent resistance by removing leftover tumor cells that survive first inhibitor therapy. Furthermore, PROTACs have exhibited substantial promise for conjunction with immune checkpoint inhibitors, where degradation of immunosuppressive proteins or oncogenic regulators may boost antigen presentation, increase cytotoxic T-cell infiltration, and improve anticancer immune responses. Additional combinations including chemotherapy, radiation, antibody-drug conjugates (ADCs), epigenetic treatments, and DNA damage response inhibitors are now under active development and may further increase therapeutic success. Future precision oncology techniques will likely incorporate biomarker-guided therapy sequencing based on genetic profiling, proteomic studies, and mechanisms of acquired resistance to enhance patient outcomes.

Beyond Oncology:-

Although oncology remains the core focus of PROTAC research, the adaptability of targeted protein degradation has generated rising interest in its applicability across several non-oncological disorders defined by abnormal protein accumulation or dysregulated signaling cascades. The catalytic mechanism of PROTACs permits persistent depletion of pathogenic proteins, making this technology especially appealing for chronic disorders in which long-term reduction of disease-driving proteins is essential.

In neurodegenerative disorders, brain-penetrant PROTACs are being developed to selectively degrade aggregation-prone proteins such as tau, α -synuclein, huntingtin, TAR DNA-binding protein 43 (TDP-43), and mutant superoxide dismutase 1 (SOD1), which contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and related disorders. By removing harmful protein aggregates rather than just suppressing their activity, PROTACs may offer disease-modifying therapeutic benefits capable of delaying neurodegeneration. Similarly, autoimmune and inflammatory illnesses constitute another intriguing field for targeted protein breakdown. Selective degradation of cytokine receptors, Janus kinases (JAKs), Bruton tyrosine kinase (BTK), STAT transcription factors, and NF- κ B signaling components may inhibit abnormal immune activation while limiting the systemic immunosuppression associated with traditional therapy.

Targeted protein breakdown also offers tremendous potential for infectious disorders by selective removal of viral proteins or host factors needed for pathogen reproduction. PROTACs targeting proteins implicated in the life cycles of human immunodeficiency virus (HIV), hepatitis viruses, influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have exhibited interesting preclinical efficacy. Moreover, continued advances in ligand discovery are expected to extend PROTAC technology to historically "undruggable" proteins, including transcription factors, scaffolding proteins, RNA-binding proteins, chromatin-associated regulators, and large

multiprotein complexes that have remained beyond the reach of conventional pharmacological approaches. Collectively, these developments indicate that targeted protein degradation is evolving beyond a cancer-specific therapeutic strategy into a versatile platform with broad applications across multiple disease areas, thereby establishing PROTACs as one of the most innovative drug discovery technologies in modern medicine.

Conclusion:-

The twenty-year journey from the initial PROTAC idea to FDA-approved therapies is one of the most extraordinary translational success stories in contemporary drug research. By radically reinventing how tiny compounds might interact with the proteome, PROTAC technology has broadened the bounds of what is deemed "druggable" and established protein degradation as a proven therapeutic method. The approval of vepdegestrant for ESR1-mutated breast cancer represents not an endpoint but a beginning. With over 30 PROTACs now in clinical trials and a large pipeline of next-generation degraders under preclinical research, the area is primed for ongoing expansion and diversity.

Yet considerable obstacles persist. The physicochemical qualities of PROTACs continue to offer formulation and delivery issues. Resistance mechanisms are starting to appear in clinical settings. The entire spectrum of off-target effects yet to be defined. And the promise of degrading really "undruggable" targets-transcription factors, scaffolding proteins, protein aggregates-has yet to be completely fulfilled.

The solutions to these challenges will likely come from continued innovation across multiple fronts: novel E3 ligase ligands that enable more selective and orally bioavailable degraders; advanced delivery systems that overcome tissue penetration barriers; artificial intelligence-driven design tools that optimize ternary complex formation; and emerging TPD modalities that extend beyond the proteasome to harness autophagy, lysosomes, and other degradation pathways.

As we move forward the next decade of targeted protein degradation, the goal that motivated the original PROTAC experiments-that we may destroy disease-causing proteins rather than just suppress them-has progressed from aspirational notion to clinical reality. The continuing refining of this technology promises to produce breakthrough treatments for patients with malignancies and other disorders that have, until now, remained outside the reach of pharmaceutical intervention.

Ethical Approval:-

This review article is based exclusively on previously published scientific literature and does not involve any experiments conducted by the authors on human participants or animals. Therefore, ethical approval was not required for the preparation of this manuscript.

Conflict of Interest:-

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

Funding:-

The authors received no financial support from any funding agency, commercial organization, or not-for-profit institution for the preparation of this review.

References:-

1. Ahn, S., Workman, C. J., & Vignali, D. A. A. (2021). Synthetic ligands for targeted protein degradation in cancer therapy. *Annual Review of Cancer Biology*, 5, 181–200.
2. Akutsu, M., Ye, Y., & Virdee, S., et al. (2019). Molecular basis for ubiquitin chain assembly and recognition. *Nature Reviews Molecular Cell Biology*, 20(7), 430–447.
3. Amaan, M., Saboor, S., & Hussain, S. A. (2022). Deep learning-based brain tumor detection. *International Journal of Advanced Research*, 10(7), 552–562.
4. An, J., & Totoki, T. (2020). Targeted protein degradation: A promise for undruggable proteins. *Cell Chemical Biology*, 27(5), 591–592.
5. U.S. Food and Drug Administration. (2026, May 1). FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
6. Bai, L., Zhou, H., & Doshi, R. (2024). PRosettaC: Rosetta-based modeling of PROTAC-mediated ternary complexes. *Journal of Chemical Information and Modeling*, 60(6), 2844–2853.

7. Bai, L., Zhou, H., & Xu, R., et al. (2024). Construction of PROTAC-mediated ternary complex structure distribution profiles using extensive conformational search. *Journal of Chemical Information and Modeling*. Advance online publication.
8. Banik, S. M., Pedram, K., & Wisnovsky, S., et al. (2020). Lysosome-targeting chimeras for degradation of extracellular proteins. *Nature*, 584(7822), 291–297.
9. Bard, J. A., Goodall, E. A., & Greene, E. R., et al. (2018). Structure and function of the 26S proteasome. *Annual Review of Biochemistry*, 87, 697–724.
10. Bekes, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: The past is prologue. *Nature Reviews Drug Discovery*, 21(3), 181–200.
11. Bondeson, D. P., Mares, A., & Smith, I. E., et al. (2015). Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nature Chemical Biology*, 11(8), 611–617.
12. Bradner, J. E., Duda, D. G., & Gray, N. S. (2021). Covalent protein degradation through bifunctional chemistry. *Current Opinion in Chemical Biology*, 62, 50–58.
13. Bradner, J. E., Rahl, P. B., & Young, R. A. (2015). Transcriptional addiction in cancer. *Cell*, 163(1), 27–35.
14. Brand, M., Jiang, B., & Bauer, S., et al. (2021). Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. *Cell Chemical Biology*, 26(2), 300–306.
15. Buckley, D. L., Raina, K., & Darricarrere, N., et al. (2015). HaloPROTACs: Use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. *ACS Chemical Biology*, 10(8), 1831–1837.
16. Burslem, G. M., & Crews, C. M. (2020). Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. *Cell*, 181(1), 102–114.
17. Burslem, G. M., Smith, B. E., & Lai, A. C., et al. (2018). The advantages of targeted protein degradation over inhibition: An RTK case study. *Cell Chemical Biology*, 25(1), 67–77.
18. Caianiello, D., Sorrentino, A., & Ciardiello, D. (2025). Navigating PROTACs in cancer therapy: Advancements, challenges, and future horizons. *Food Science & Nutrition*, 13(1), e70011.
19. Chamberlain, P. P., & Hamann, L. G. (2019). Development of targeted protein degradation therapeutics. *Nature Chemical Biology*, 15(10), 937–944.
20. Chamberlain, P. P., Lopez-Girona, A., & Miller, K., et al. (2014). Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. *Nature Structural & Molecular Biology*, 21(9), 803–809.
21. Churcher, I. (2018). PROTAC-induced protein degradation in drug discovery: Breaking the rules or just making new ones? *Journal of Medicinal Chemistry*, 61(2), 444–452.
22. Cromm, P. M., Samarasinghe, K. T., & Hines, J., et al. (2015). Addressing kinase-independent functions of Fak via PROTAC-mediated degradation. *Journal of the American Chemical Society*, 137(15), 5031–5034.
23. Ding, Y., Fei, Y., & Lu, B. (2020). Emerging protein degradation strategies: Expanding the scope to extracellular and membrane proteins. *Life Science Alliance*, 3(12), e202000718.
24. Dong, G., Ding, Y., & He, S., et al. (2021). Molecular glues for targeted protein degradation: From serendipity to rational discovery. *Journal of Medicinal Chemistry*, 64(15), 10606–10620.
25. Drummond, M. L., & Williams, C. I. (2019). In silico prediction of PROTAC structural motifs and linkers. *Journal of Chemical Information and Modeling*, 59(12), 4947–4958.
26. Drummond, M. L., Williams, C. I., & Tiwary, P. (2020). Predicting the future of PROTACs: Predictive molecular dynamics for higher throughput targeted protein degradation. *Frontiers in Chemistry*, 8, 585.
27. Fan, Y., Zhang, L., & Wu, X. (2025). Proteolysis-targeting chimera (PROTAC): Current applications and future directions. *MedComm*, 6(1), e70401.
28. Filippakopoulos, P., Qi, J., & Picaud, S., et al. (2010). Selective inhibition of BET bromodomains. *Nature*, 468(7327), 1067–1073.
29. Fischer, E. S., Böhm, K., & Lydeard, J. R., et al. (2014). Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. *Nature*, 512(7512), 49–53.
30. Gadd, M. S., Testa, A., & Lucas, X., et al. (2017). Structural basis of PROTAC cooperative recognition for selective protein degradation. *Nature Chemical Biology*, 13(5), 514–521.
31. Galdeano, C., Gomez-Pinto, I., & Lucas, X., et al. (2014). Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit. *Journal of Medicinal Chemistry*, 57(20), 8657–8663.
32. Gorfe, A. A., & McCammon, J. A. (2023). Computational design of PROTACs: Challenges and opportunities. *Current Opinion in Structural Biology*, 78, 102548.
33. Han, X., Wang, C., & Qin, C., et al. (2019). Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands. *Journal of Medicinal Chemistry*, 62(22), 11218–11231.

34. Han, X., Zhao, L., & Xie, W. (2023). Emerging E3 ligases for targeted protein degradation. *Cell Chemical Biology*, 30(2), 112–128.
35. Hanzl, A., Winter, G. E., & Ettmayer, P. (2022). Current strategies for the design of PROTAC linkers: A critical review. *Exploration of Targeted Anti-tumor Therapy*, 3, 100218.
36. Hanzl, A., Winter, G. E., & Ettmayer, P. (2022). Molecular glues: The adhesive connecting targeted protein degradation to the clinic. *Cancer Research*, 82(15), 2711–2725.
37. Hartmann, J. T., & Lipp, H. P. (2023). Toxicity of targeted protein degraders: Clinical and regulatory considerations. *Drug Safety*, 46(8), 789–802.
38. Hines, J., Gough, J. D., & Corson, T. W., et al. (2013). Posttranslational protein knockdown coupled to receptor recycling by the sortilin-related receptor. *Journal of the American Chemical Society*, 135(23), 8479–8482.
39. Hoi, K. K., & Chan, K. H. (2022). From conception to development: Investigating PROTACs features for improved cell permeability and successful protein degradation. *Frontiers in Chemistry*, 9, 672267.
40. Hu, Z., Li, Y., & Zhang, C. (2022). Recent developments in PROTAC-mediated protein degradation: From bench to clinic. *ChemBioChem*, 23(5), e202100270.
41. Huang, H., Sun, L., & Liu, C. (2023). Uncovering the kinetic characteristics and degradation preference of PROTAC systems with advanced theoretical analyses. *JACS Au*, 3(8), 2287–2301.
42. Hurvitz, S. A., Bardia, A., & Bedard, P. L., et al. (2023). Phase 1b study of ARV-471, a PROTAC estrogen receptor degrader, plus palbociclib in patients with metastatic ER+/HER2- breast cancer. *Cancer Research*, 83(5_Supplement), PD13-04.
43. Ibrahim, M., Al Saeed, M., & El-Tanani, M. (2024). Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology. *Cancer Communications*, 44(3), 245–267.
44. Ito, T., Ando, H., & Suzuki, T., et al. (2010). Identification of a primary target of thalidomide teratogenicity. *Science*, 327(5971), 1345–1350.
45. Klein, V. G., Townsend, P. A., & Testa, A. (2020). Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action. *ACS Chemical Biology*, 15(6), 1516–1527.
46. Komander, D., & Rape, M. (2012). The ubiquitin code. *Annual Review of Biochemistry*, 81, 203–229.
47. Krop, I. E., Juric, D., & Shimizu, T., et al. (2022). ARV-471, an estrogen receptor (ER) PROTAC degrader, in ER+/HER2- advanced breast cancer: Phase 1 study results. *Journal of Clinical Oncology*, 40(16_suppl), 1017.
48. Li, Y., Yang, J., & Aguilar, A. (2022). Recent advances in the development of Pro-PROTAC for selective protein degradation. *Pharmaceutics*, 16(3), 343.
49. Li, Z., Ding, N., & Zhao, K. (2023). Targeting the undruggables-The power of protein degraders. *Med*, 4(5), 302–327.
50. Li, Z., Zhu, C., & Ding, Y., et al. (2019). ATTEC: A potential new approach to target proteinopathies. *Autophagy*, 15(5), 918–919.
51. Lu, J., Qian, Y., & Altieri, M., et al. (2015). Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. *Chemistry & Biology*, 22(6), 755–763.
52. Lu, M., Liu, T., & Jiao, Q., et al. (2018). Discovery of a Keap1-dependent peptide PROTAC for the targeted degradation of the BCR-ABL oncoprotein. *ChemBioChem*, 19(16), 1727–1731.
53. Matyskiela, M. E., Lu, G., & Ito, T., et al. (2016). A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. *Nature*, 535(7611), 252–257.
54. Mayor-Ruiz, C., & Winter, G. E. (2020). From crude to critical: Assessing the proteome-wide activity of molecular glues. *Cell Chemical Biology*, 27(10), 1119–1121.
55. Mayor-Ruiz, C., Bauer, S., & Brand, M., et al. (2020). Rational discovery of molecular glue degraders via scalable chemical profiling. *Nature Chemical Biology*, 16(11), 1199–1207.
56. Mullard, A. (2021). Targeted protein degraders face manufacturing hurdles. *Nature Reviews Drug Discovery*, 20(4), 247–249.
57. Nicodeme, E., Jeffrey, K. L., & Schaefer, U., et al. (2010). Suppression of inflammation by a synthetic histone mimic. *Nature*, 468(7327), 1119–1123.
58. Ohtake, F., Tsuchiya, H., & Saeki, Y., et al. (2018). K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains. *Proceedings of the National Academy of Sciences*, 115(7), E1401–E1408.
59. Petteruti, P., de Bono, J., & Brown, M., et al. (2022). ARV-110: An androgen receptor PROTAC degrader for the treatment of metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, 40(6_suppl), TPS311.
60. Pfizer Inc. (2023, January). Arvinas and Pfizer's vepdegestrant (ARV-471) receives FDA Fast Track designation for the treatment of patients with ER+/HER2- metastatic breast cancer.[Press release]
61. Pillay, S., Wang, D., & Mincheva, M. (2023). Orally bioavailable proteolysis-targeting chimeras: An innovative approach in the golden era of discovering small-molecule cancer drugs. *Molecular Biomedicine*, 4(1), 12.

62. Raina, K., Lu, J., & Qian, Y., et al. (2016). PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. *Proceedings of the National Academy of Sciences*, 113(26), 7124–7129.
63. Reinstein, E., Ciechanover, A., & Schwartz, A. L. (2020). The ubiquitin-proteasome system: A potential target for cancer therapy. *Biochimica et Biophysica Acta*, 1867(11), 118432.
64. Roy, M. J., Winkler, S., & Hughes, S. J., et al. (2019). Structural basis of PROTAC cooperative recognition for selective protein degradation. *Nature Chemical Biology*, 15(7), 716–723.
65. Sakamoto, K. M., Kim, K. B., & Kumagai, A., et al. (2001). Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. *Proceedings of the National Academy of Sciences*, 98(15), 8554–8559.
66. Santos, R., & Paolini, G. V. (2023). The hook effect in PROTACs: Mechanistic insights and clinical implications. *Drug Discovery Today*, 28(4), 103532.
67. Schapira, M., Calabrese, M. F., & Bullock, A. N., et al. (2019). Targeted protein degradation: Expanding the toolbox. *Nature Reviews Drug Discovery*, 18(12), 949–963.
68. Schneekloth, A. R., Pucheault, M., & Tae, H. S., et al. (2008). Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. *Bioorganic & Medicinal Chemistry Letters*, 18(22), 5904–5908.
69. Schneekloth, J. S., Jr., Fonseca, F. N., & Koldobskiy, M., et al. (2004). Chemical genetic control of protein levels and selective protein degradation using bivalent chemical adaptors. *Journal of the American Chemical Society*, 126(12), 3748–3754.
70. Silva, M. C., Ferguson, F. M., & Cai, Q., et al. (2020). Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. *eLife*, 8, e45457.
71. Smith, B. E., Wang, S. L., & Jaime-Figueroa, S., et al. (2019). Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. *Nature Communications*, 10(1), 131.
72. Sun, D., Wu, R., & Cai, Y., et al. (2023). Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier. *Biomedicines*, 12(3), 43.
73. Sun, Y., Zhao, X., & Ding, N., et al. (2020). PROTAC-induced BTK degradation as a novel therapy for mutated BTKC481S induced ibrutinib-resistant B-cell malignancies. *Cell Research*, 29(4), 270–272.
74. Swatek, K. N., & Komander, D. (2016). Ubiquitin modifications. *Cell Research*, 26(4), 399–422.
75. Takahashi, D., Moriyama, J., & Nakamura, T., et al. (2019). AUTACs: Small-molecule-targeted protein degradation through the autophagy-lysosome pathway. *Nature Communications*, 10(1), 5494.
76. Tao, Y., & Lee, Y. T. (2023). Resolving enzyme–substrate–activator ambiguity: A minimalist enzyme kinetic framework for PROTAC design and optimization. *Journal of Medicinal Chemistry*, 66(23), 15871–15887.
77. Toure, M., & Crews, C. M. (2016). Small-molecule PROTACS: New approaches to protein degradation. *Angewandte Chemie International Edition*, 55(6), 1966–1973.
78. Van Molle, I., Thomann, A., & Buckley, D. L., et al. (2012). Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1 α protein-protein interface. *Chemistry & Biology*, 19(10), 1300–1312.
79. Wang, C., Zhang, Y., & Yu, W., et al. (2024). PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review. *International Journal of Biological Macromolecules*, 261, 129864.
80. Wang, Y., Jiang, X., & Zhang, T., et al. (2024). PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review. *International Journal of Biological Macromolecules*, 261, 129864.
81. Wang, Y., Liu, X., & Qin, C. (2023). Research progress of PROTACs for neurodegenerative diseases therapy. *Bioorganic & Medicinal Chemistry*, 89, 117534.
82. Wang, Y., Yang, C., & Wang, S. (2024). PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation. *Pharmaceutics*, 17(4), 501.
83. Winter, G. E., Buckley, D. L., & Paulk, J., et al. (2015). Phthalimide conjugation as a strategy for in vivo target protein degradation. *Science*, 348(6241), 1376–1381.
84. Wurz, R. P., Dellamaggiore, J., & Dou, H., et al. (2023). Navigating the proteome with high-affinity reagents: Insights for drug discovery. *Nature Communications*, 14, 3218.
85. Yang, C., Wang, S., & Zhou, H. (2024). Methods to accelerate PROTAC drug discovery. *Nature Reviews Drug Discovery*. Advance online publication.
86. Yau, R. G., Doerner, K., & Castellanos, E. R., et al. (2017). Assembly and function of heterotypic ubiquitin chains in cell-cycle and protein quality control. *Cell*, 171(4), 918–933.
87. Zengerle, M., Chan, K. H., & Ciulli, A. (2015). Selective small molecule induced degradation of the BET bromodomain protein BRD4. *ACS Chemical Biology*, 10(8), 1770–1777.
88. Zheng, M., Liu, J., & Jin, Q., et al. (2022). Targeted protein degradation: Mechanisms, strategies and application. *Signal Transduction and Targeted Therapy*, 7(1), 113.